2019 年第 9 期 第 14 卷

甘草酸二铵对稳定期慢性阻塞性肺疾病的临床疗效及对患者血清炎性因子和外周血T淋巴细胞水平的影响

Clinical efficacy of diammonium glycyrrhizinate treating stable chronic obstructive pulmonary disease and the effect on serum inflammatory factors and peripheral blood T lymphocytes

作者：方妮周鸿江陈俊健

英文作者：

单位：530000南宁，广西医科大学第二附属医院呼吸内科

英文单位：

关键词：慢性阻塞性肺疾病；甘草酸二铵；稳定期；炎性因子；免疫功能

英文关键词：

• 摘要：

• 【摘要】目的    探讨甘草酸二铵对稳定期慢性阻塞性肺疾病(COPD)的临床疗效及对患者血清炎性因子和外周血T淋巴细胞水平的影响。方法    选取2015年1月至2017年6月于广西医科大学第二附属医院就诊的稳定期COPD患者123例作为研究对象，按照随机数字表法分为观察组（62例）和对照组（61例）。对照组给予常规治疗，观察组在对照组基础上加用甘草酸二铵胶囊150 mg/次，3次/d口服治疗，2组均治疗3个月。比较2组患者临床疗效、肺功能指标、血清炎性因子和外周血T淋巴细胞水平的变化。结果    观察组总有效率高于对照组［90.3%（56/62）比75.4%（46/61）］，差异有统计学意义（χ2=4.830，P=0.028）。治疗前，2组患者肺功能指标、血清炎症指标及外周血T淋巴细胞水平比较差异均无统计学意义(均P＞0.05)。治疗后，2组患者的第1秒用力呼气容积（FEV1)、用力肺活量（FVC）、FEV1/FVC比值均明显高于治疗前，且观察组高于对照组；2组患者的血清C反应蛋白、白细胞介素6和肿瘤坏死因子α水平均明显低于治疗前，且观察组低于对照组，差异均有统计学意义（均P<0.05）。治疗后观察组CD+3、CD+4、CD+4/CD+8比值水平高于对照组，CD+8水平低于对照组，差异均有统计学意义（均P＜0.01）。观察组和对照组不良反应率差异无统计学意义［9.7%（6/62）比6.6%（4/61）］(P＞0.05)。结论    COPD稳定期患者采取常规治疗同时联用甘草酸二铵胶囊可提高临床疗效，改善患者肺功能，减轻炎症反应，增强免疫功能，且不增加药物不良反应的发生率。

• 【Abstract】Objective    To investigate the clinical effect of diammonium glycyrrhizinate on patients with stable chronic obstructive pulmonary disease(COPD) and the effect on serum inflammatory factors and peripheral blood T lymphocytes. Methods    A total of 123 patients with stable COPD hospitalized in the Second Affiliated Hospital of Guangxi Medical University from January 2015 to June 2017 were randomly divided into observation group(62 cases) and control group(61 cases). The control group was treated with routine therapy. The observation group took diammonium glycyrrhizinate capsule 150 mg, three times daily on the basis of routine therapy. Both groups were treated for 3 months. Clinical efficacy, pulmonary function, serum inflammatory factors and peripheral blood T lymphocytes were analyzed. Results    Total effective rate in observation group was significantly higher than that in control group［90.3%(56/62) vs 75.4%(46/61)］(χ2=4.830, P=0.028). There were no significant differences in pulmonary function indexes, serum inflammation factors and peripheral blood T lymphocytes between groups before treatment(all P>0.05). After treatment, forced expiratory volume in the first second(FEV1), forced vital capacity(FVC) and FEV1/FVC significantly increased in both groups; the indexes in observation group were significantly higher than those in control group; serum levels of C-reactive protein, interleukin-6 and tumor necrosis factor-α significantly decreased in both groups; the levels in observation group were significantly lower than those in control group(all P<0.05). After treatment, levels of CD+3, CD+4, CD+4/CD+8 in observation group were significantly higher and the level of CD+8 was lower than those in control group(all P<0.01). There was no significant difference in adverse reaction rate between observation group and control group［9.7%(6/62) vs 6.6%(4/61)］(P>0.05). Conclusion    Diammonium glycyrrhizinate capsule combined with conventional treatment treating COPD patients at stable stage can improve the clinical efficacy, improve lung function, alleviate inflammatory response and enhance immune function, without increasing the incidence of adverse drug reactions.